摘要目的 评价HAG方案(高三尖杉酯碱+阿糖胞苷+粒细胞集落刺激因子)治疗高危骨髓增生异常综合征(MDS)的疗效和安全性.方法 回顾性分析2008-2010年14家医院97例高危MDS患者进行HAG预激方案诱导缓解治疗的疗效.结果 总完全缓解率为52.3％ (45/86),总有效率为66.3％(57/86).早期病死率为9.3％ (9/97).年龄≥60岁的患者与年龄＜60岁的患者完全缓解率及总有效率差异均无统计学意义(均P＞0.05).按染色体核型判断预后,预后好、预后中度和预后差的患者的诱导治疗总有效率分别为29/34、9/12和6/13,预后好的治疗总有效率高于预后差的(P=0.038).不良反应主要为感染.结论 HAG方案治疗高危MDS有较高的完全缓解率和总有效率.

abstractsObjective To evaluate the efficacies and toxicity of HAG ( HHT + Ara-C + G-CSF)regimen in patients with high-risk myelodysplastic syndromes(MDS).Methods A total of 97 patients with high-risk MDS received HAG regimen as the induction therapy.Results The comp山ete remission (CR) rate of all the patients was 52.3％ (45/86).The overall response (OR) rate was 66.3％ (57/86).The early mortality rate was 9.3％ (9/97).There was no significant difference in CR rate and OR rate between the patients aged≥ 60 and those ＜60.The OR rate was 29/34,9/12 and 6/13 in patients with favorable karyotype,intermediate karyotype and unfavorable karyotype respectively. The OR rate was higher in patients with favorable karyotype than those with unfavorable karyotype ( P =0.038 ).The major adverse effect was infection.Conclusion HAG regimen provides higher CR rate and OR rate for patients with highrisk MDS.